SLC5A2 and heart failure: In addition to their antihyperglycemic effects and concurrent lower risk of hypoglycemia, the GLP-1 receptor agonists and SGLT2 inhibitors demonstrated significant benefits for patients with atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease [6,7].